Silver Spring, Maryland—(ENEWSPF)—October 9, 2017
By U.S. Food & Drug Administration (FDA)
The U.S. Food and Drug Administration approved a new treatment option for patients who have been diagnosed with moderate to severe central sleep apnea. The Remedē System is an implantable device that stimulates a nerve located in the chest that is responsible for sending signals to the diaphragm to stimulate breathing.
“This implantable device offers patients another treatment option for central…
